Cargando…
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
Cancer cells are characterized by a higher rate of protein turnover and greater demand for protein homeostasis compared to normal cells. In this scenario, the ubiquitin–proteasome system (UPS), which is responsible for the degradation of over 80% of cellular proteins within mammalian cells, becomes...
Autores principales: | Zhang, Xiaonan, Linder, Stig, Bazzaro, Martina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226376/ https://www.ncbi.nlm.nih.gov/pubmed/32272746 http://dx.doi.org/10.3390/cancers12040902 |
Ejemplares similares
-
Dienone Compounds: Targets and Pharmacological Responses
por: Bazzaro, Martina, et al.
Publicado: (2020) -
Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries
por: Zhang, Xiaonan, et al.
Publicado: (2021) -
Targeting Mitochondria for Treatment of Chemoresistant Ovarian Cancer
por: Emmings, Edith, et al.
Publicado: (2019) -
Ubiquitin–proteasome system (UPS) as a target for anticancer treatment
por: Park, Jinyoung, et al.
Publicado: (2020) -
The Ubiquitin-Proteasome System (UPS) as a Cancer Drug Target: Emerging Mechanisms and Therapeutics
por: Mata-Cantero, Lydia, et al.
Publicado: (2014)